BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28056412)

  • 1. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.
    Kroeze SG; Fritz C; Hoyer M; Lo SS; Ricardi U; Sahgal A; Stahel R; Stupp R; Guckenberger M
    Cancer Treat Rev; 2017 Feb; 53():25-37. PubMed ID: 28056412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Radiation therapy and targeted therapies: Risks and opportunities].
    Nicolas E; Lucia F
    Cancer Radiother; 2022 Oct; 26(6-7):973-978. PubMed ID: 36057520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review.
    Belgioia L; Desideri I; Errico A; Franzese C; Daidone A; Marino L; Fiore M; Borghetti P; Greto D; Fiorentino A;
    Crit Rev Oncol Hematol; 2019 Jan; 133():163-170. PubMed ID: 30661652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of "real" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review.
    Trapani S; Manicone M; Sikokis A; D'Abbiero N; Salaroli F; Ceccon G; Buti S
    Crit Rev Oncol Hematol; 2019 Oct; 142():9-15. PubMed ID: 31325712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases.
    Trino E; Mantovani C; Badellino S; Ricardi U; Filippi AR
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):347-356. PubMed ID: 28277101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries.
    Kroeze SGC; Fritz C; Basler L; Gkika E; Brunner TB; Grosu AL; Guckenberger M
    Strahlenther Onkol; 2019 Mar; 195(3):199-206. PubMed ID: 30737541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
    Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
    Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
    Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous Complications of Targeted Melanoma Therapy.
    de Golian E; Kwong BY; Swetter SM; Pugliese SB
    Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy and radiotherapy for metastatic cancers.
    Bang A; Schoenfeld JD
    Ann Palliat Med; 2019 Jul; 8(3):312-325. PubMed ID: 30180743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
    Brade AM; Ng S; Brierley J; Kim J; Dinniwell R; Ringash J; Wong RR; Cho C; Knox J; Dawson LA
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):580-7. PubMed ID: 26867886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy.
    Pollom EL; Deng L; Pai RK; Brown JM; Giaccia A; Loo BW; Shultz DB; Le QT; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):568-76. PubMed ID: 26068491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
    Jarkowski A; Norris L; Trinh VA
    Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review.
    Lancellotta V; Del Regno L; Di Stefani A; Fionda B; Marazzi F; Rossi E; Balducci M; Pampena R; Morganti AG; Mangoni M; Lebbe C; Garbe C; Longo C; Schinzari G; Tagliaferri L; Peris K
    Radiol Med; 2022 Jul; 127(7):773-783. PubMed ID: 35606609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis.
    Kroeze SGC; Fritz C; Schaule J; Blanck O; Kahl KH; Kaul D; Siva S; Gerum S; Claes A; Sundahl N; Adebahr S; Stera S; Schymalla MM; Abbasi-Senger N; Buergy D; Geier M; Szuecs M; Lohaus F; Henke G; Combs SE; Guckenberger M
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
    Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
    J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.